Drugs.com - Clinical Trials

Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial

PRINCETON, N.J.-- April 14, 2025 (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association...

May 12, 2025 - 09:53
 0
Bristol Myers Squibb Provides Update on Camzyos Phase 3 ODYSSEY-HCM Trial
PRINCETON, N.J.-- April 14, 2025 (BUSINESS WIRE) -- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association...
Read More

Tags:

Previous Article

Click Therapeutics Announces FDA Marketing Authorization for CT-132, the First P...

Next Article

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Related Posts

Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations

Merck Announces MK-1084, an Investigational KRAS G12C I...

Jun 3, 2025  0

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Granted Three U.S. FDA Fast Track Designations...

May 12, 2025  0

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

May 12, 2025  0